Gene Solutions has unveiled SPOTMAS Lung, an innovative blood-based test powered by artificial intelligence (AI) and multiomics analysis, designed to enhance early lung cancer detection in Asia. This new test is particularly significant for asymptomatic individuals and those with inconclusive imaging results, who are often overlooked by traditional screening methods.
Lung cancer remains a major health concern in Asia, accounting for 62% of global lung cancer deaths. Alarmingly, nearly half of the patients in the region are diagnosed at a metastatic stage, where curative treatment is often not possible. Early detection, however, can dramatically improve survival rates, making the SPOTMAS Lung test a crucial development.
The test analyses circulating tumour DNA (ctDNA) shed by cancer cells, using a multiomics tumour atlas and AI models trained on Asian population data. This approach aims to make advanced testing more affordable whilst maintaining high sensitivity and specificity. Notably, the test has shown no significant difference in performance between smokers and non-smokers, making it particularly useful in regions where lung cancer in never-smokers is prevalent.
Gene Solutions has partnered with 365 Cancer Prevention Society and Bethesda Medical Centre in Singapore to offer free tests as part of a public health initiative. This collaboration aims to increase awareness and expand access to early detection, aligning with Gene Solutions’ mission to provide accessible, precision-based cancer screening.
A multicentre validation study is planned in Singapore to further assess the test’s performance. Prof Anand Sachithanandan, Founding President of Lung Cancer Network Malaysia, highlighted the test’s potential to address the unmet need for early diagnosis in high-risk non-smokers.
“`
